Cost-utility analysis in depression: The McSad utility measure for depression health states

被引:36
|
作者
Bennett, KJ
Torrance, GW
Boyle, MH
Guscott, R
机构
[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[3] McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON L8S 4L8, Canada
[4] McMaster Univ, Sch Business, Hamilton, ON L8S 4L8, Canada
关键词
D O I
10.1176/appi.ps.51.9.1171
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Cost-utility analysis, used increasingly over the past decade to analyze costs and effects in treating physical diseases, has received little attention in psychiatry. This article briefly introduces the concepts and methods of utility measurement and illustrates it using depression as an example. The authors describe the McSad health state classification system for depression, a direct utility measure for depression, and report results of an application of McSad among 105 patients who had a recent history of depression. Utility measures express patient preferences for specific health states on a scale ranging from 0, representing death, to 1, representing perfect health. These scores provide the weights used to calculate the number of quality-adjusted Life-years gained by an intervention or set-vice. McSad allows a patient's depression health state to be classified according to level of functioning in six dimensions of depression and to be compared with other hypothetical depression health states in order to produce utility scores indicating the patient's relative preferences.
引用
收藏
页码:1171 / 1176
页数:6
相关论文
共 50 条
  • [21] Preferences for health outcomes and cost-utility analysis
    Torrance, GW
    AMERICAN JOURNAL OF MANAGED CARE, 1997, 3 : S8 - S20
  • [22] Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
    Degerlund Maldi, Kinza
    Asellus, Peter
    Myleus, Anna
    Norstrom, Fredrik
    BMC PSYCHIATRY, 2021, 21 (01)
  • [23] Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
    Kinza Degerlund Maldi
    Peter Asellus
    Anna Myléus
    Fredrik Norström
    BMC Psychiatry, 21
  • [24] Decision tree-Markov model of perinatal depression screening: a cost-utility analysis
    Yang, Yehuan
    Zheng, Ruimin
    Yang, Li
    Huang, Xing
    Zhang, Tong
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [25] Assessing outcomes for cost-utility analysis in depression: comparison of five multi-attribute utility instruments with two depression-specific outcome measures
    Mihalopoulos, Cathrine
    Chen, Gang
    Lezzi, Angelo
    Khan, Munir A.
    Richardson, Jeffrey
    BRITISH JOURNAL OF PSYCHIATRY, 2014, 205 (05) : 390 - 397
  • [26] Assigning values to intermediate health states for cost-utility analysis: Theory and practice
    Cohen, BJ
    MEDICAL DECISION MAKING, 1996, 16 (04) : 376 - 385
  • [27] Methods for Measuring Temporary Health States for Cost-Utility Analyses
    Davene R. Wright
    Eve Wittenberg
    J. Shannon Swan
    Rebecca A. Miksad
    Lisa A. Prosser
    PharmacoEconomics, 2009, 27 : 713 - 723
  • [28] Methods for Measuring Temporary Health States for Cost-Utility Analyses
    Wright, Davene R.
    Wittenberg, Eve
    Swan, J. Shannon
    Miksad, Rebecca A.
    Prosser, Lisa A.
    PHARMACOECONOMICS, 2009, 27 (09) : 713 - 723
  • [29] COST-UTILITY ANALYSIS IN UROLOGY
    Fero, Katherine
    Sharma, Vidit
    Lec, Patrick
    Saigal, Christopher
    Chamie, Karim
    JOURNAL OF UROLOGY, 2021, 206 : E435 - E436
  • [30] Cost-utility analysis for UTIs
    Schaefer, SE
    JOURNAL OF FAMILY PRACTICE, 1997, 44 (04): : 329 - 329